Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
Staflin K, Zuch de Zafra CL, Schutt LK, Clark V, Zhong F, Hristopoulos M, Clark R, Li J, Mathieu M, Chen X, Johnston J, Low J, Ybarra R, Slaga D, Yang J, Ovacik M, Dybdal NO, Totpal K, Junttila MR, Ellerman D, Lee G, Dennis MS, Prell R, Junttila TT. Staflin K, et al. Among authors: junttila tt, junttila mr. JCI Insight. 2020 Apr 9;5(7):e133757. doi: 10.1172/jci.insight.133757. JCI Insight. 2020. PMID: 32271166 Free PMC article.
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A. Junttila TT, et al. Among authors: junttila mr. Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16. Cancer Res. 2014. PMID: 25228655
Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation.
Long JE, Wongchenko MJ, Nickles D, Chung WJ, Wang BE, Riegler J, Li J, Li Q, Sandoval W, Eastham-Anderson J, Modrusan Z, Junttila T, Carano RAD, Foreman O, Yan Y, Junttila MR. Long JE, et al. Among authors: junttila mr, junttila t. Cell Death Differ. 2019 Nov;26(11):2416-2429. doi: 10.1038/s41418-019-0310-0. Epub 2019 Mar 1. Cell Death Differ. 2019. PMID: 30824837 Free PMC article.
Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
Daemen A, Cooper JE, Myrta S, Wongchenko MJ, Lin E, Long JE, Foreman O, Modrusan Z, Tremayne JR, de la Cruz CC, Merchant M, Martin SE, Yan Y, Junttila MR. Daemen A, et al. Among authors: junttila mr. Clin Cancer Res. 2021 Feb 15;27(4):1162-1173. doi: 10.1158/1078-0432.CCR-20-1835. Epub 2020 Oct 6. Clin Cancer Res. 2021. PMID: 33023953
Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment.
Riegler J, Labyed Y, Rosenzweig S, Javinal V, Castiglioni A, Dominguez CX, Long JE, Li Q, Sandoval W, Junttila MR, Turley SJ, Schartner J, Carano RAD. Riegler J, et al. Among authors: junttila mr. Clin Cancer Res. 2018 Sep 15;24(18):4455-4467. doi: 10.1158/1078-0432.CCR-17-3262. Epub 2018 May 24. Clin Cancer Res. 2018. PMID: 29798909
Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer.
Junttila MR, Mao W, Wang X, Wang BE, Pham T, Flygare J, Yu SF, Yee S, Goldenberg D, Fields C, Eastham-Anderson J, Singh M, Vij R, Hongo JA, Firestein R, Schutten M, Flagella K, Polakis P, Polson AG. Junttila MR, et al. Sci Transl Med. 2015 Nov 18;7(314):314ra186. doi: 10.1126/scitranslmed.aac7433. Sci Transl Med. 2015. PMID: 26582901
53 results